131 related articles for article (PubMed ID: 29076598)
1. A comprehensive in vitro and in vivo metabolism study of hydroxysafflor yellow A.
Wu L; Tang Y; Shan C; Chai C; Zhou Z; Shi X; Ding N; Wang J; Lin L; Tan R
J Mass Spectrom; 2018 Feb; 53(2):99-108. PubMed ID: 29076598
[TBL] [Abstract][Full Text] [Related]
2. UFLC-Q-TOF/MS based screening and identification of the metabolites in plasma, bile, urine and feces of normal and blood stasis rats after oral administration of hydroxysafflor yellow A.
Jin Y; Wu L; Tang Y; Cao Y; Li S; Shen J; Yue S; Qu C; Shan C; Cui X; Zhang L; Duan JA
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():124-9. PubMed ID: 26827279
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs.
Chu D; Liu W; Huang Z; Liu S; Fu X; Liu K
Planta Med; 2006 Apr; 72(5):418-23. PubMed ID: 16557455
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of hydroxysafflor yellow A in patients with traumatic brain injury after intravenous administration of Xuebijing using LC-MS/MS method.
Sheng C; Peng W; Xia Z; Wang Y
Xenobiotica; 2020 May; 50(5):545-551. PubMed ID: 31524030
[TBL] [Abstract][Full Text] [Related]
5. Measurement of hydroxysafflor yellow A in human urine by liquid chromatography-tandem mass spectrometry.
Li CY; Chu JH; Zhang J; Sun BT; Dai GL; Liu SJ; Ju WZ
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():131-7. PubMed ID: 25463208
[TBL] [Abstract][Full Text] [Related]
6. LC-Q-TOF/MS-oriented systemic metabolism study of pedunculoside with in vitro and in vivo biotransformation.
Wu L; Kang A; Shan C; Chai C; Zhou Z; Lin Y; Bian Y
J Pharm Biomed Anal; 2019 Oct; 175():112762. PubMed ID: 31336286
[TBL] [Abstract][Full Text] [Related]
7. Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats.
Xu RA; Xu ZS; Ge RS
J Ethnopharmacol; 2014 Feb; 151(3):1141-1146. PubMed ID: 24373810
[TBL] [Abstract][Full Text] [Related]
8. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of hydroxysafflor yellow A in human plasma: application to a pharmacokinetic study.
Wen A; Yang J; Jia Y; Yang Z; Tian Y; Wu Y; Wang Z; He Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(1):41-6. PubMed ID: 18964371
[TBL] [Abstract][Full Text] [Related]
9. Hydroxysafflor yellow A cardioprotection in ischemia-reperfusion (I/R) injury mainly via Akt/hexokinase II independent of ERK/GSK-3β pathway.
Min J; Wei C
Biomed Pharmacother; 2017 Mar; 87():419-426. PubMed ID: 28068632
[TBL] [Abstract][Full Text] [Related]
10. Determination of hydroxysafflor yellow A in biological fluids of patients with traumatic brain injury by UPLC-ESI-MS/MS after injection of Xuebijing.
Guo Y; Wang Y; Huang X; Lv H; Fan R; Huang W; Gan P; Liu W; Yan K; Xia Z; Liu J
Biomed Chromatogr; 2014 Aug; 28(8):1090-5. PubMed ID: 24535782
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice.
Yao R; Cao Y; Jiang R; Zhang X; Li F; Wang S
Biomed Chromatogr; 2021 Oct; 35(10):e5173. PubMed ID: 33982286
[TBL] [Abstract][Full Text] [Related]
12. Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats.
Li L; Dong P; Hou C; Cao F; Sun S; He F; Song Y; Li S; Bai Y; Zhu D
J Ethnopharmacol; 2016 Jun; 186():224-233. PubMed ID: 27063983
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Study on Protocatechuic Aldehyde and Hydroxysafflor Yellow A of Danhong Injection in Rats with Hyperlipidemia.
Zhou J; Li M; Jin W; Li X; Fan H; Zhang Y
Pharmacology; 2018; 102(3-4):154-160. PubMed ID: 30045035
[TBL] [Abstract][Full Text] [Related]
14. [Studies on pharmacokinetics of hydroxysafflor yellow A in Carthamus tinctorius and its compound preparation in rat].
Tang J; Ouyang Z; Feng X; Fang J; Cao X
Zhongguo Zhong Yao Za Zhi; 2011 Aug; 36(16):2246-9. PubMed ID: 22097340
[TBL] [Abstract][Full Text] [Related]
15. Exploring in vitro, in vivo metabolism of mogroside V and distribution of its metabolites in rats by HPLC-ESI-IT-TOF-MS(n).
Xu F; Li DP; Huang ZC; Lu FL; Wang L; Huang YL; Wang RF; Liu GX; Shang MY; Cai SQ
J Pharm Biomed Anal; 2015 Nov; 115():418-30. PubMed ID: 26280925
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic effect of Sappan Lignum on hydroxysafflor yellow A in Carthami Flos].
Xia L; Chen XM; Peng LR; Wang SX; Wang XW; Zuo Y; Zhang P; Liu QS; Zheng XH
Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(2):269-72. PubMed ID: 23672054
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies.
Zhu H; Wang Z; Ma C; Tian J; Fu F; Li C; Guo D; Roeder E; Liu K
Planta Med; 2003 May; 69(5):429-33. PubMed ID: 12802724
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats.
He Y; Liu Q; Li Y; Yang X; Wang W; Li T; Zhang W; Cui Y; Wang C; Lin R
J Physiol Biochem; 2015 Mar; 71(1):69-78. PubMed ID: 25626885
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of hydroxysafflor yellow A on PDGF‑BB‑induced proliferation and migration of vascular smooth muscle cells via mediating Akt signaling.
Song Y; Long L; Zhang N; Liu Y
Mol Med Rep; 2014 Sep; 10(3):1555-60. PubMed ID: 24939805
[TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A.
Zhao B; Gu S; Du Y; Shen M; Liu X; Shen Y
Int J Pharm; 2018 Jan; 535(1-2):164-171. PubMed ID: 29107614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
